Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2007 09:52 ET | Source: Samaritan Pharmaceuticals, Inc.

Georgetown University and Samaritan Sign Exclusive Licensing Agreement for Novel Treatment of Cushing's Syndrome

LAS VEGAS, Aug. 8, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it has entered into an exclusive licensing agreement with...
August 02, 2007 10:05 ET | Source: Samaritan Pharmaceuticals, Inc.

Samaritan's Chief Drug Development Officer to Present Lead Alzheimer's Drug At 12th IBC World Congress

Focus Area: New and Emerging Therapeutic Targets for CNS Topic: SP-233: A New and Novel Therapy With Protective Properties Against the Neurotoxic Effects of Beta-Amyloid Peptide LAS VEGAS,...
July 30, 2007 10:22 ET | Source: Samaritan Pharmaceuticals, Inc.

Samaritan Exclusively Licenses Innovative Blood Diagnostic to Uncover Whether Breast Tumor is Cancer

Blood Test Can Detect One Single Aggressive Cancer Cell Out of Millions of Normal Blood Cells Diagnostic Technology Thought to Detect Prostrate and Colon ...
July 25, 2007 10:01 ET | Source: Samaritan Pharmaceuticals, Inc.

Samaritan Therapeutics Signs Research Collaboration and Licensing Agreement With The Research Institute of McGill University Health Centre

LAS VEGAS, July 25, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, and Samaritan Therapeutics, Canada, is pleased to announce it has signed a...
July 24, 2007 09:49 ET | Source: Samaritan Pharmaceuticals, Inc.

Samaritan Licenses Exclusive Rights to Infectious Disease Compounds From Georgetown University

LAS VEGAS, July 24, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it has entered into an exclusive license agreement with...
July 20, 2007 07:00 ET | Source: Samaritan Pharmaceuticals, Inc.

Samaritan Announces Positive Preliminary Results in a Phase IIb Study For Its Novel Oral HIV Entry Inhibitor

LAS VEGAS, July 20, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce its novel oral HIV entry inhibitor SP-01A, being...
July 10, 2007 09:35 ET | Source: Samaritan Pharmaceuticals, Inc.

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

Animal Study Confirms Caprospinol's (SP-233) Ability to Clear Brain Plaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct Correlation...
June 28, 2007 15:44 ET | Source: Samaritan Pharmaceuticals, Inc.

Samaritan Reorganizes Its Stock Structure

LAS VEGAS, June 28, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative life-saving drugs, announced today its Board of Directors has unanimously decided to...
June 12, 2007 10:58 ET | Source: Samaritan Pharmaceuticals, Inc.

Nationally Recognized M.D. Joins Samaritan Pharmaceuticals' Board of Directors

LAS VEGAS, June 12, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative life saving drugs, announces Doug Bessert has decided for personal reasons to step...
June 07, 2007 09:40 ET | Source: Samaritan Pharmaceuticals, Inc.

Samaritan in Collaboration With UCSD Awarded NIH Grant for the Continued Development of Samaritan's Compounds to Suppress HIV Viral Replication and Prevent Neuronal Damage

LAS VEGAS, June 7, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce the National Institutes of Health (NIH) has awarded a...